R. Wernyj

Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma In Situ by Vitamin D Compounds

P. Furmanski, N. Shan, A. Minden, 2020, Cancer Prevention Research.

Expression of calbindin-D28k in C6 glial cells stabilizes intracellular calcium levels and protects against apoptosis induced by calcium ionophore and amyloid beta-peptide.

M. Mattson, R. Wernyj, S. Christakos, 1999, Brain research. Molecular brain research.

Modulation of specific protein expression levels by PTEN: identification of AKAP121, DHFR, G3BP, Rap1, and RCC1 as potential targets of PTEN

M. Seminario, R. Wange, R. Wernyj, 2005, Oncogene.

Multiple antibodies to titin immunoreact with AHNAK and localize to the mitotic spindle machinery.

W. Isaacs, C. Ewing, R. Wernyj, 2001, Cell motility and the cytoskeleton.

Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3.

R. Wernyj, S. Christakos, M. Raval-Pandya, 1996, The Biochemical journal.

Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression

Kathleen R. Cho, D. Schwartz, P. Morin, 2003, Oncogene.

Crucial Roles of Sp1 and Epigenetic Modifications in the Regulation of the CLDN4 Promoter in Ovarian Cancer Cells*

Hiroshi Honda, M. Pazin, P. Morin, 2006, Journal of Biological Chemistry.

Molecular mechanisms of platinum resistance: still searching for the Achilles' heel.

P. Morin, R. Wernyj, Patrice J Morin, 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Identification of Function for CD44 Intracytoplasmic Domain (CD44-ICD)

D. Foran, M. Reiss, Wenjin Chen, 2012, The Journal of Biological Chemistry.

CRUCIAL ROLES OF SP 1 AND EPIGENETIC MODIFICATIONS IN THE REGULATION OF THE CLDN 4 PROMOTER IN OVARIAN CANCER CELLS *

M. Pazin, P. Morin, R. Wernyj, 2006 .

CD44 promotes multi-drug resistance by protecting P-glycoprotein from FBXO21-mediated ubiquitination

R. Wernyj, K. Madura, L. Rodriguez-Rodriguez, 2015, Oncotarget.